Orchestra BioMed Holdings, Inc.
OBIO
$2.78
$0.207.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.42% | -26.49% | -52.15% | -42.16% | -21.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.42% | -26.49% | -52.15% | -42.16% | -21.88% |
| Cost of Revenue | 9.68% | 0.52% | -19.81% | -17.37% | -11.85% |
| Gross Profit | -5.44% | -28.01% | -53.77% | -43.62% | -22.52% |
| SG&A Expenses | 18.13% | 14.46% | 24.83% | 36.18% | 44.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.35% | 19.63% | 23.85% | 31.92% | 49.95% |
| Operating Income | -24.84% | -23.03% | -31.29% | -39.18% | -57.72% |
| Income Before Tax | -24.23% | -25.26% | -29.19% | -33.04% | -46.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.23% | -25.26% | -29.19% | -33.04% | -46.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.23% | -25.26% | -29.19% | -33.04% | -46.16% |
| EBIT | -24.84% | -23.03% | -31.29% | -39.18% | -57.72% |
| EBITDA | -24.94% | -23.14% | -31.43% | -39.31% | -57.91% |
| EPS Basic | -11.48% | 0.36% | 9.77% | 32.11% | 37.70% |
| Normalized Basic EPS | -13.92% | 3.01% | 10.52% | 36.11% | 40.49% |
| EPS Diluted | -11.48% | 0.36% | 9.77% | 32.11% | 37.70% |
| Normalized Diluted EPS | -13.92% | 3.01% | 10.52% | 36.11% | 40.49% |
| Average Basic Shares Outstanding | 11.02% | 22.59% | 38.24% | 79.99% | 121.82% |
| Average Diluted Shares Outstanding | 11.02% | 22.59% | 38.24% | 79.99% | 121.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |